BioMarin (BMRN) CTO Guyer sells 16,486 shares in open-market trade

Rhea-AI Filing Summary

BioMarin Pharmaceutical EVP and Chief Technical Officer Charles Greg Guyer sold common shares in an open-market transaction. On March 11, 2026, he sold 16,486 shares of BioMarin common stock at a weighted average price of $60.46 per share, with individual sale prices ranging from $60.39 to $60.62. After this sale, he directly held 79,953 shares of BioMarin common stock.

Insights

Equity governance analyst

Routine executive share sale with substantial remaining holdings.

Executive vice president and Chief Technical Officer Charles Greg Guyer executed an open-market sale of 16,486 shares of BioMarin common stock at a weighted average price of $60.46 on March 11, 2026. The transaction is a standard insider sale rather than an option exercise or tax-related event.

Following the sale, he directly holds 79,953 shares, indicating he retained a sizable equity position. The footnote clarifies that the reported price is a weighted average, with sale prices ranging between $60.39 and $60.62, suggesting multiple trades executed within a narrow range.

The filing does not reference a pre-arranged trading plan such as Rule 10b5-1 in the provided excerpt, so the timing context is not specified. Subsequent Form 4 filings, if any, will further clarify whether this sale is part of a broader pattern of insider trading activity.

Insider Trade Summary

Net Seller: 16,486 shares

Net Sell 1 txn

Insider Guyer Charles Greg

Role EVP, Chief Technical Officer

Sold 16,486 shs ($997K)

Type	Security	Shares	Price	Value
Sale	Common Stock	16,486	$60.46	$997K

Holdings After Transaction: Common Stock — 79,953 shares (Direct)

Footnotes (1)

1. F1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.39 to $60.62. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 03/12/2026 - 07:55 PM Learn about SEC filing dates

FAQ

What did BioMarin (BMRN) executive Charles Greg Guyer report in his latest Form 4?

Executive Charles Greg Guyer reported an open-market sale of BioMarin common stock. He sold 16,486 shares on March 11, 2026 at a weighted average price of $60.46 per share, and directly held 79,953 shares after the transaction.

How many BioMarin (BMRN) shares did Charles Greg Guyer sell and at what price?

Charles Greg Guyer sold 16,486 shares of BioMarin common stock. The weighted average sale price was $60.46 per share, with individual trades executed in a narrow range between $60.39 and $60.62, as disclosed in the Form 4 footnote.

What is Charles Greg Guyer’s remaining BioMarin (BMRN) shareholding after this Form 4 sale?

After selling 16,486 shares, Charles Greg Guyer directly holds 79,953 shares of BioMarin common stock. This remaining position, disclosed in the Form 4, shows he continues to maintain a significant personal equity stake in the company following the open-market sale.

What role does Charles Greg Guyer hold at BioMarin (BMRN) in this Form 4 filing?

In this Form 4, Charles Greg Guyer is identified as an officer of BioMarin, serving as Executive Vice President and Chief Technical Officer. The filing links his insider status and senior leadership role to the disclosed open-market sale of company common stock.

Was the BioMarin (BMRN) insider transaction a purchase or a sale of shares?

The transaction was a sale of shares. The Form 4 shows an open-market sale of 16,486 shares of BioMarin common stock by executive Charles Greg Guyer, coded as an “S” transaction with the description “Sale in open market or private transaction.”

Does the BioMarin (BMRN) Form 4 detail the price range for the insider share sale?

Yes. A footnote explains that the reported $60.46 is a weighted average sale price. The actual prices received for the 16,486 BioMarin shares sold ranged from $60.39 to $60.62, and detailed breakdown information is available upon request.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer Charles Greg

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		S		16,486	D	$60.46(1)	79,953	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price in column 4 is the weighted average price. The purchase price actually received ranged from $60.39 to $60.62. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.